Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG)

Key facts

Sponsor

Oregon Health and Science University

Principal Investigator

Alex G Ortega-Loayza, MD, MCR

Oregon Health & Science University, Department of Dermatology

Intervention

Baricitinib(drug)

Enrollment

5 enrolled

Eligibility

18-99 years · All sexes

Timeline

2023 – 2025

Study locations (1)

• Oregon Health and Science University, Portland, Oregon, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Classic pyoderma gangrenosum

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE3NCT06624670
  A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum
  Boehringer Ingelheim
• RECRUITINGPHASE2NCT06563323
  Guselkumab in the Treatment of Adults With Pyoderma Gangrenosum (PG)
  Oregon Health and Science University

See all trials for Classic pyoderma gangrenosum →